Adverse Drug Reaction Reporting in Nigeria: A Practical Guide for Pharmaceutical Companies

Regulatory note: This guide draws on NAFDAC's Nigerian Guidelines for Detecting and Reporting of Adverse Reactions for Pharmaceutical Products and Medical Devices (2024) and its Good Pharmacovigilance Practice Guidelines (2021). Requirements should be confirmed against the current edition of each guideline.

Quick answer: In Nigeria, pharmaceutical companies must capture, assess and report suspected adverse drug reactions to NAFDAC as part of their pharmacovigilance obligations. A valid report, an Individual Case Safety Report (ICSR), needs four minimum elements: an identifiable patient, an identifiable reporter, a suspected medicine and a suspected reaction. Causality does not need to be proven before reporting. The reporting clock can start as soon as anyone in the company becomes aware of a valid case, so every staff member who may receive safety information must know how to escalate it to the pharmacovigilance function without delay.

Introduction

A medicine's safety monitoring does not end when it receives regulatory approval. Once a product enters the market, pharmaceutical companies must continue identifying, assessing and reporting potential safety concerns. This ongoing activity is known as pharmacovigilance, and adverse drug reaction (ADR) reporting is one of its essential components.

In Nigeria, the National Agency for Food and Drug Administration and Control (NAFDAC) oversees pharmacovigilance activities. For manufacturers, importers, distributors and Marketing Authorisation Holders (MAHs), an effective ADR reporting process supports patient safety and regulatory compliance. This guide outlines the essentials companies need to understand and implement.

1. What Is an Adverse Drug Reaction?

An adverse drug reaction is a harmful and unintended response associated with the use of a medicinal product. Examples may include anaphylaxis following administration of a medicine, gastrointestinal bleeding associated with certain medicines, hypoglycaemia linked to antidiabetic treatment or liver injury associated with drug exposure.

A suspected reaction should be reported even when causality has not been confirmed. Pharmacovigilance systems collect and assess safety signals; reporters do not need to prove that a medicine caused the event.

2. Why ADR Reporting Matters to Pharmaceutical Companies

Clinical trials cannot identify every possible adverse reaction. They may involve limited populations, controlled conditions and relatively short treatment periods. Wider use after approval can reveal safety concerns that were not apparent earlier.

• Detect emerging risks: reports can identify previously unrecognised reactions or changes in known risks. Our guide to signal detection in pharmacovigilance explains how this works.
• Protect patients: timely safety information supports appropriate risk-minimisation and regulatory action.
• Meet regulatory responsibilities: companies need documented processes for receiving, assessing and reporting safety information.
• Maintain product oversight: ADR data contributes to ongoing benefit-risk evaluation and post-marketing surveillance.

3. Who Should Report and Receive ADR Information?

ADR reporting involves several stakeholders. Healthcare professionals, patients and caregivers can report suspected reactions. MAHs are responsible for monitoring the safety of their products and fulfilling applicable reporting obligations. Importers, distributors and other business partners should promptly pass safety information to the relevant MAH in accordance with agreed procedures.

Within a company, medical representatives, sales and marketing teams, customer service, quality assurance, regulatory affairs and distribution personnel may receive potential safety information. Staff must know how to recognise and forward it to the pharmacovigilance function without delay.

4. What Makes an ADR Report Valid?

A valid Individual Case Safety Report (ICSR) must contain four minimum elements:

1. An identifiable patient: for example, initials, age, sex or date of birth.
2. An identifiable reporter: such as a healthcare professional, patient or caregiver.
3. A suspected medicinal product: the medicine believed to be associated with the reaction.
4. A suspected adverse reaction: a description of what happened.

These minimum elements are identified in NAFDAC's 2024 Nigerian Guidelines for Detecting and Reporting Adverse Reactions. If information is incomplete, the report should not simply be abandoned; the company should make appropriate follow-up attempts.

Additional Information to Collect

• Product name, strength, dosage form, route and dose; batch or lot number, where available.
• Dates treatment started, stopped and the reaction began.
• Reaction description, seriousness, outcome and treatment given.
• Relevant medical history, concomitant medicines and laboratory findings.
• Whether the medicine was withdrawn or reintroduced.

5. A Practical ADR Reporting Process

1. Receive: Create accessible channels for safety information, including company email, customer service, medical representatives, patient support programmes, distributors and relevant digital channels.
2. Document and validate: Record the information using an approved form or system. Check whether the four minimum ICSR criteria are present and follow up on missing details.
3. Assess: Evaluate seriousness, expectedness, the suspected relationship to the medicine, clinical outcome and other relevant factors. Severity of intensity and regulatory seriousness are not the same thing.
4. Submit and retain records: Submit valid reports according to current NAFDAC requirements. Keep submission evidence, correspondence and case documentation.
5. Follow up: Seek additional clinical information where appropriate and update cases when significant new information becomes available.

For what happens once a report reaches the regulator, see what happens after you report an adverse event to NAFDAC.

6. Reporting Timelines: What Companies Should Know

Timelines are a critical part of pharmacovigilance compliance. NAFDAC's Good Pharmacovigilance Practice (GVP) Guidelines (2021) specify the following post-registration reporting timelines:

Regulatory caution: These periods are reproduced from the 2021 GVP guideline and should not be treated as confirmation that they remain the current requirements for every product or reporting situation. NAFDAC has also issued a 2024 adverse reaction reporting guideline. Before implementing a timeline, companies should verify the latest applicable NAFDAC guidance, product-specific conditions and subsequent regulatory directives.

Why Day Zero Matters

The reporting clock may begin when relevant company personnel or representatives first become aware of information meeting the minimum criteria for a valid report, not only when the PV department receives or formally opens the case. Companies therefore need clear internal escalation procedures and staff training.

7. Common Gaps and How to Strengthen the System

Frequent weaknesses include low staff awareness, incomplete case information, delayed escalation, missing SOPs, inadequate follow-up and limited management oversight. Companies can address these gaps through a coordinated pharmacovigilance system:

• Assign clear PV responsibilities and appoint appropriately qualified personnel in line with applicable requirements.
• Maintain SOPs for intake, validation, assessment, reporting, follow-up and record retention.
• Train relevant employees and third parties to recognise and forward safety information.
• Establish written safety information exchange arrangements with distributors and service providers.
• Maintain an organised case database and monitor reporting deadlines.
• Conduct periodic PV audits, compliance reviews and inspection-readiness checks.
• Maintain required system documentation, including a PSMF where applicable, and manage RMPs and PSURs where required.

Our article on pharmacovigilance compliance mistakes Nigerian pharma companies make covers these weaknesses in more depth.

8. ADR Reporting and NAFDAC Inspections

During a pharmacovigilance inspection, a company may be asked to demonstrate how its system works in practice. Relevant evidence can include assigned responsibilities, SOPs, ADR case records, submission and follow-up evidence, staff training records, third-party agreements, audit reports and quality-management documentation.

Having a reporting form is not enough. Companies should be able to show that safety information is captured, escalated, assessed, submitted when required and retained appropriately.

Conclusion

ADR reporting is a core pharmacovigilance activity and an important responsibility for pharmaceutical companies operating in Nigeria. A reliable system depends on trained personnel, accessible reporting channels, clear procedures, timely escalation and appropriate oversight. Beyond supporting regulatory compliance, these activities help identify medicine-related risks and protect patients throughout a product's lifecycle.

Frequently Asked Questions

What is the difference between an adverse event and an adverse drug reaction?

An adverse event is an untoward medical occurrence following medicine use, without necessarily establishing a causal relationship. An adverse drug reaction involves a suspected causal relationship between the medicine and the reaction.

What makes an ADR report valid in Nigeria?

A valid Individual Case Safety Report (ICSR) must contain four minimum elements: an identifiable patient, an identifiable reporter, a suspected medicinal product and a suspected adverse reaction. These are identified in NAFDAC's 2024 Nigerian Guidelines for Detecting and Reporting Adverse Reactions.

Should a suspected ADR be reported if causality has not been confirmed?

Yes. A suspected reaction should be reported even when causality has not been confirmed. Pharmacovigilance systems collect and assess safety signals; reporters do not need to prove that a medicine caused the event.

When does the ADR reporting clock start?

The reporting clock may begin when relevant company personnel or representatives first become aware of information meeting the minimum criteria for a valid report, not only when the pharmacovigilance department receives or formally opens the case.

What are NAFDAC's ADR reporting timelines?

NAFDAC's 2021 Good Pharmacovigilance Practice Guidelines state 72 hours for serious, unexpected local ADRs and significant safety issues, 15 calendar days for serious, expected and non-serious, unexpected local ADRs, and within 90 days for non-serious, expected local ADRs. Companies should verify the latest applicable NAFDAC guidance before implementing any timeline.

What do NAFDAC inspectors look for in ADR reporting?

Evidence that the system works in practice: assigned responsibilities, SOPs, ADR case records, submission and follow-up evidence, staff training records, third-party agreements, audit reports and quality-management documentation.

How MedNova Lifesciences Can Support Your Pharmacovigilance Needs

MedNova Lifesciences supports pharmaceutical companies seeking to establish, strengthen or assess their pharmacovigilance systems. Our areas of support include:

• PV system establishment and gap assessments.
• ADR reporting processes and SOP development.
• Pharmacovigilance training for pharmaceutical personnel, including our Pharmacovigilance CE Course.
• PSMF development and maintenance support.
• RMP and PSUR preparation.
• PV audits and inspection-readiness support.
• QPPV support, as applicable.

Related reading: the complete guide to pharmacovigilance in Nigeria, NAFDAC pharmacovigilance requirements, GVP compliance in Nigeria, and the resources library.

References and Further Reading

1. NAFDAC. Nigerian Guidelines for Detecting and Reporting of Adverse Reactions for Pharmaceutical Products and Medical Devices (2024).

2. NAFDAC. Good Pharmacovigilance Practice Guidelines (2021).

3. World Health Organization. Pharmacovigilance and the monitoring of medicine safety.

Editorial note: This article provides general regulatory information and should not replace review of the latest applicable NAFDAC requirements or product-specific regulatory instructions.